<DOC>
	<DOCNO>NCT02798913</DOCNO>
	<brief_summary>The objective present study evaluate prognostic impact prolong dual antiplatelet therapy ( DAPT ) acetylsalicylic acid plus clopidogrel incidence major adverse cardiovascular event major adverse limb event percutaneous low extremity revascularization patient low extremity peripheral arterial disease ( LE-PAD ) .</brief_summary>
	<brief_title>Effects Prolonged DAPT After Lower Extremity Percutaneous Transluminal Angioplasty ( PTA ) Patients With LE-PAD</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>LEPAD stage 2 Fontaine 's classification ( intermittent claudication ) successful PTA aortoiliac , femoropopliteal ore belowtheknee segment critical limb ischemia recent acute coronary syndrome ( &lt; 12 month ) recent cerebrovascular event ( &lt; 12 month ) recent myocardial , carotid peripheral revascularization ( &lt; 12 month ) recent history bleeding ( &lt; 12 month ) indication clopidogrel therapy indication anticoagulation decompensated heart failure malignant neoplasm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>dual antiplatelet therapy</keyword>
	<keyword>peripheral transluminal angioplasty</keyword>
</DOC>